Gracon Adam S A, Wilkes David S
Department of Surgery and Center for Immunobiology, Indiana University School of Medicine, Indianapolis, IN, USA.
Departments of Medicine, Microbiology and Immunology, Center for Immunobiology, Indiana University School of Medicine, Indianapolis, IN, USA.
Hum Immunol. 2014 Aug;75(8):887-94. doi: 10.1016/j.humimm.2014.06.015. Epub 2014 Jun 27.
Despite significant medical advances since the advent of lung transplantation, improvements in long-term survival have been largely unrealized. Chronic lung allograft dysfunction, in particular obliterative bronchiolitis, is the primary limiting factor. The predominant etiology of obliterative bronchiolitis involves the recipient's innate and adaptive immune response to the transplanted allograft. Current therapeutic strategies have failed to provide a definitive treatment paradigm to improve long-term outcomes. Inducing immune tolerance is an emerging therapeutic strategy that abrogates allograft rejection, avoids immunosuppression, and improves long-term graft function. The aim of this review is to discuss the key immunologic components of obliterative bronchiolitis, describe the state of establishing immune tolerance in transplantation, and highlight those strategies being evaluated in lung transplantation.
尽管自肺移植出现以来医学取得了重大进展,但长期生存率的提高在很大程度上尚未实现。慢性肺移植功能障碍,尤其是闭塞性细支气管炎,是主要的限制因素。闭塞性细支气管炎的主要病因涉及受体对移植同种异体移植物的固有和适应性免疫反应。目前的治疗策略未能提供明确的治疗模式来改善长期预后。诱导免疫耐受是一种新兴的治疗策略,可消除同种异体移植物排斥反应,避免免疫抑制,并改善长期移植物功能。本综述的目的是讨论闭塞性细支气管炎的关键免疫成分,描述移植中建立免疫耐受的状态,并强调在肺移植中正在评估的那些策略。